Figure 7.
Chronic antitumor efficacy of the novel PARPi AZD2461. A, overall survival of mice receiving 100 days of olaparib (see also ref. 9) or AZD2461 treatment. After relapse of a tumor to a size of 100%, treatment was given for another 100 days. Individual tumor responses are shown in Supplementary Fig. S10A–S10C. B, relapse-free survival of mice with a KB1P tumor that received AZD2461 for 28 consecutive days or for 100 consecutive days. The Gehan–Breslow–Wilcoxon P values are indicated.